Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial (Q33417361)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase III clinical trial

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

15

object named as

Peter Hau

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

object named as

Louis Burt Nabors

31

0 references

object named as

Monika E Hegi

2

0 references

37

object named as

Michael Weller

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

12

object named as

Wolfgang Wick

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

David A Reardon

32

object named as

David A Reardon

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Astrid Weyerbrock

object named as

Astrid Weyerbrock

16

1 reference

ORCID Public Data File 2021

Rafał Tarnawski

13

object named as

Rafał Tarnawski

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Alba A. Brandes

26

object named as

Alba A Brandes

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

22

object named as

Tejpal Gupta

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Martin J van den Bent

33

object named as

Martin J van den Bent

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kenneth D Aldape

7

object named as

Kenneth D Aldape

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Rolf-Dieter Kortmann

23

object named as

Rolf-Dieter Kortmann

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

object named as

Roger Stupp

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

3

object named as

Thierry Gorlia

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

4

object named as

Sara C Erridge

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ulrich Herrlinger

21

object named as

Ulrich Herrlinger

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Catherine McBain

25

object named as

Catherine McBain

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jörg-Christian Tonn

27

object named as

Joerg Christian Tonn

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Martin Taphoorn

17

object named as

Martin J B Taphoorn

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

James Perry

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yong-Kil Hong

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Benoit Lhermitte

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Torsten Pietsch

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Danica Grujicic

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Joachim Peter Steinbach

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Do-Hyun Nam

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Chiung-Chyi Shen

18

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Nalini Rao

19

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

László Thurzo

20

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Krystyna Adamska

24

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Oliver Schnell

28

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Thomas Wiegel

29

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Chae-Yong Kim

30

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Christine Hicking

34

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Andriy Markivskyy

35

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Martin Picard

36

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

European Organisation for Research and Treatment of Cancer (EORTC)

38

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Canadian Brain Tumor Consortium

39

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

CENTRIC study team

40

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

19 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1100-1108

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Glioblastoma survival in the United States before and during the temozolomide era.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug resistance in glioblastoma: a mini review

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrin control of the transforming growth factor-β pathway in glioblastoma.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrins in cancer: biological implications and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Will integrin inhibitors have proangiogenic effects in the clinic?

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of bevacizumab for newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)70379-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70379-1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33417361&oldid=2015151882"